15825 Shady Grove Road
Suite 135
Rockville, MD 20850
United States
410-297-7793
https://www.ostherapies.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 3
Nombre | Título | Paga | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Paul A. Romness M.P.H. | Founder, President, CEO & Director | 360k | N/A | 1966 |
Dr. Robert G. Petit Ph.D. | Chief Medical Officer & Chief Scientific Officer | 300k | N/A | 1960 |
Mr. Christopher P. Acevedo | Chief Financial Officer | N/A | N/A | 1963 |
Mr. Jack Doll | Chief of Staff | N/A | N/A | N/A |
Mr. Gerald E. Commissiong | Chief Business Officer | N/A | N/A | 1982 |
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy; and OST-TDC, a next generation tunable antibody-drug conjugate with a plug-and-play platform that features tunable pH sensitive silicone linkers. It offers treatment for treatments for OsteoSarcoma. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.
El ISS Governance QualityScore de OS Therapies Incorporated, a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.